Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Aberrant activation of oncogenes or loss of tumour suppressor genes opposes malignant transformation by triggering a stable arrest in cell growth, which is termed cellular senescence. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumour cells to senescence. Whether tumour-infiltrating immune cells can oppose senescence is unknown. Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth. Mechanistically, we found that Gr-1(+) cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA). Strikingly, Pten-loss-induced cellular senescence was enhanced in vivo when Il1ra knockout myeloid cells were adoptively transferred to PTEN null mice. Therapeutically, docetaxel-induced senescence and efficacy were higher in PTEN null tumours when the percentage of tumour-infiltrating CD11b(+)Gr-1(+) myeloid cells was reduced using an antagonist of CXC chemokine receptor 2 (CXCR2). Taken together, our findings identify a novel non-cell-autonomous network, established by innate immunity, that controls senescence evasion and chemoresistance. Targeting this network provides novel opportunities for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, during cancer development associated with accumulation of senescent cells, SASP can recruit immature myeloid cells to promote tumorigenesis in a paracrine manner160,161.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [160]
In the citing paper
“Further, the SASP can recruit immature immune-suppressive myeloid cells to prostate and liver tumors (Di Mitri et al., 2014; Eggert et al., 2016) and stimulate tumorigenesis by driving angiogenesis and metastasis (Coppe ´ et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Di Mitri et al., 2014
In the citing paper
“In some instances, the SASP can also have immunosuppressive functions (Di Mitri et al. 2014; Eggert et al. 2016).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Di Mitri et al. 2014
In the citing paper
“Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers166–172.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [167]
In the citing paper
“There is convergent evidence that this occurs via the recruitment of myeloid-derived suppressor cells (MDSCs) chemoattracted by factors (e.g., IL-6, IL-8, and CCL2) secreted by senescent cells in murine models of HCC, 193 prostate, 194 and skin cancers.195”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [194]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Self-citationOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Self-citation
Cited by
Items 301–400 of 409
Garlanda, C., & Jaillon, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.10001-3 · Cited by 8
Chen, J., Gong, L., Cao, S., Song, G., Peng, Y., Wang, Y., Lou, Y., Murtola, T. J., Wu, Y., Yu, G., et al. (2025) · Theranostics · doi:10.7150/thno.114534 · Cited by 5
Self-citationZhang, C., Zhan, Z., Zhang, Y., & Chen, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-14455-5 · Cited by 6
Xu, T., Huang, J., Liu, Y., Lu, L., Lovell, J. F., Zhu, M., & Jin, H. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01260-6 · Cited by 6
“…by senescent cells could remodel the TME and promote the recruitment of immunosuppressive cells 17 , and Di Mitri et al., who also showed that senescence-associated molecular signals induced the in fi ltra-tionofmyeloid-derivedsuppressorcellsandcreatedanimmunosuppressive microenvironment 18 .”
Zhou, H., Liu, C., Hu, F., Shen, C., Shen, B. Q., He, W., & Du, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12066 · Cited by 5
“Under these conditions, MDSCs become chronic inflammatory cells that impair protective immune responses, which lead to an inability to clear infec‐ tion, increased tissue damage from autoimmune responses, and a failure to restore tissue homeostasis and regulate tissue repair (12).”
BackgroundPeng, J., Yang, Q., Jiang, H., Wang, Y., Liu, Q., Xiao, Y., & Qian, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102087 · Cited by 5
Yur, M., Balın, Ş. Ö., Aygen, E., İlhan, Y. S., Yılmaz, S., & Ebiloğlu, M. F. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2239033 · Cited by 5
Prognostic Biomarkers for Hodgkin Lymphoma
Staege, M. S., Kewitz, S., Bernig, T., Kühnöl, C. D., & Mauz‐Körholz, C. (2015) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2015.1071903 · Cited by 5
“[117] Di Mitri D, Toso A, Chen JJ, et al.”
BackgroundLiu, S., Pan, W., Cheng, Z., Sun, G., Zhu, P., Chan, F. L., Hu, Y., Zhang, X., & Dai, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.7479 · Cited by 5
MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
Yuan, H., Wang, X., Jin, L., Zhang, Q., Brandina, I., Alexandrov, I. M., & Glazer, R. I. (2018) · Oncotarget · doi:10.18632/oncotarget.24233 · Cited by 5
“Cxcl1 modulates MDSC infiltration in prostate tumors [35] and rhabdomyosarcomas [26], is a prognostic marker of poor outcome in breast cancer [36] and promotes metastasis in an MDA-MB-231 breast cancer xenograft model [18].”
BackgroundSong, Q., Wu, J., Wang, S., & Xu, S. (2021) · Future Oncology · doi:10.2217/fon-2021-0371 · Cited by 5
Dormant mechanisms reveal the clinical significance of tumor dormancy: a narrative review
Chang, Y., & Chen, J. (2021) · Annals of Blood · doi:10.21037/aob-20-46 · Cited by 6
“Some senescent tumor cells can be regarded as dormant tumor cells, which can be restored to proliferate when the immune system is weakened (90-96).”
BackgroundSelf-citationBujanda, Z. A. L., Hadavi, S. H., de Porras, V. R., Martinez‐Balibrea, E., & Dallos, M. C. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.008 · Cited by 6
Senescent cancer cells in immune surveillance and evasion: mechanisms and therapeutic implications
De-chang, L., Wang, J., Wei, Y., Wu, H. Y., Yuan, S., Yang, M. J., & Sun, L. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf125 · Cited by 5
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer
Lin, C., Hadfield, M. J., Rathore, A., Pinho-Schwermann, M. P., Zhang, S., Lu, S., den Hollander, P., Mani, S. A., Seyhan, A. A., Santopietro, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103061 · Cited by 5
Immune surveillance and immune evasion of senescent cells
Garcia-Baucells, P., Serrano, M., & Amor, C. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01335-w · Cited by 6
A Conversation with ChatGPT on Contentious Issues in Senescence and Cancer Research
Elshazly, A. M., Shahin, U., Shboul, S. A., Gewirtz, D. A., & Saleh, T. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000871 · Cited by 4
“The SASP of senescent tumor cells can modulate the TME either as an anti-tumor effect via inducing growth arrest or can have immunosuppressive properties via MDSCs activity (Di Mitri et al., 2014; Salminen et al., 2018).”
BackgroundPortillo‐Miño, J. D., Calderón, J. J., Ruíz‐García, E., & Monge, C. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03960-8 · Cited by 4
Murthy, P., Zenati, M. S., AlMasri, S. S., DeSilva, A., Singhi, A. D., Paniccia, A., Lee, K. K. W., Simmons, R. L., Bahary, N., Lotze, M. T., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7070 · Cited by 9
Silva‐Álvarez, S. D., & Collado, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30066-9 · Cited by 5
Self-citationCellular Senescence in Cancer: Mechanisms, Roles in Tumor Progression, and Therapeutic Implications
Yan, J., Zhang, Y., Mao, G., Yu, J., Zhou, T., & Hao, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70029 · Cited by 3
Chen, S., Cai, W., & Liu, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1745168 · Cited by 3
Brea, L. T., Shi, H., Keo, V., Huang, J., Peng, L., Chu, Q., Xie, W., Xie, Y., Senthil, S., Breneman, M. T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71121-8 · Cited by 4
Heterogeneous characterization of neutrophilic cells in head and neck cancers
Fay, M., Clavijo, P. E., & Allen, C. T. (2024) · Head & Neck · doi:10.1002/hed.27774 · Cited by 3
“…cell growth and survival by releasing carcinogenic granules, 17 inhibit cancer cell senescence via expression of interleukin-1 receptor antagonist (IL-1Ra), 18 and drive angiogenesis by secreting vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP9) and prokineticin-2 (BV8).”
Chemokine systems in oncology: From microenvironment modulation to nanocarrier innovations
Guan, M., Liu, S., Yang, Y., Song, Y., Zhang, Y., & Sun, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131679 · Cited by 4
Tumor-Induced Myeloid-Derived Suppressor Cells
Sanctis, F. D., Bronte, V., & Ugel, S. (2017) · ASM Press eBooks · doi:10.1128/9781555819194.ch49 · Cited by 4
Silva‐Álvarez, S. D., & Collado, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00219-4 · Cited by 3
Self-citationDevelopment of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Challenges and advances in drug resistance and tolerance in cancer
Bivona, T. G., Yanai, I., Calabrò, F., Mechta‐Grigoriou, F., Corleone, G., Martile, M. D., Tocci, A., Tocci, P., Vaccarella, S., Ferriero, M., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03665-y · Cited by 2
“Cellular senescence plays a dual role in cancer: while it can suppress early tumor growth, senescent tumor cells can also promote metastasis and immunosuppression through the senescence-associated secretory phenotype (SASP) and the release of mitochondrial DNA [32, 33].”
Self-citationThe lethal symbiont: exploring the pathophysiology of cancer
Nolan, E., Li, L., Giampazolias, E., Ombrato, L., & Malanchi, I. (2026) · Physiological Reviews · doi:10.1152/physrev.00019.2025 · Cited by 2
Liu, W., Xu, W., Liu, W., Liang, R., Tang, S., Luo, X., Liu, C., Liao, Q., Sun, H., Wang, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738966 · Cited by 4
PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate
Wise, H. M., Harris, A., Kriplani, N., Schofield, A., Caldwell, H., Arends, M. J., Overton, I. M., & Leslie, N. R. (2022) · Biomolecules · doi:10.3390/biom12101511 · Cited by 2
Chemokines and Chemokine Receptors in Cancer: An Update
Elemam, N. M., & Maghazachi, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_26-1 · Cited by 3
Guo, Y., Wang, Y., Duan, J., Wan, R., Chang, G., Zhang, X., Ma, Z., Bai, H., & Wang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35940 · Cited by 3
Chen, S., Karekad, M. M. A., Liu, T., Ding, B., Wang, R., Sun, Q., Xu, X., & Shi, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1531493 · Cited by 2
Lipid peroxidation and superoxide dismutase activity in pea seedlings under clinorotation.
Бараненко, В. В. (1998) · PubMed · Cited by 2
Duxfield, A., Garnham, R., Hutton, E., Dowle, A., Wills, J., Luzzi, S., Nelson, R., Lishman-Walker, E., Magee, R., Buskin, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.15.682547 · Cited by 2
“Myeloid cells have recently been shown to be key determinants of immune suppression in prostate tumours and high numbers of CD163 + tumour associated macrophages (TAMs) in prostate tumours are predictive of poor clinical outcomes 62–64 .”
Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors
Jueliger, S., Taverna, P., Re, O. L., & Vinciguerra, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_166-1 · Cited by 1
The prostate cancer stem cell niche: Genetic drivers and therapeutic approaches
Canesin, G. (2020) · Advances in stem cells and their niches · doi:10.1016/bs.asn.2020.09.001 · Cited by 2
Cellular Senescence and Stem Cell Exhaustion: Implications for Aging and Regeneration
Kumar, N., & Walia, H. K. (2025) · Cellular Senescence, Age-Related Disorders, and Emerging Treatments · doi:10.1007/978-981-96-1041-9_6 · Cited by 1
3D models to study therapy-induced senescence: where do we stand now?
Heydari, Z., Malogolovkin, A. S., Smirnova, O., Lyukmanov, D., Filimonova, A., Shpichka, A. I., Vosough, M., & Timashev, P. S. (2025) · Cytotechnology · doi:10.1007/s10616-025-00774-y · Cited by 1
Heterogeneous neutrophils: Key players in regulating tumor immunity
Bi, W., Li, X., Zhao, H., Han, Q., & Zhang, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189538 · Cited by 1
Myeloid-derived suppressor cells promote therapy-induced resistance in prostate cancer
Liu, A., Song, P., Liu, Z., Colucci, M., Lai, P., Yang, L., Yan, X., Qiu, H., & Dong, Q. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004227 · Cited by 1
Dyskerin dysfunction in cancer development: from telomere dysregulation to immune deficiency
Xie, Y. (2026) · American Journal of Cancer Research · doi:10.62347/hjxs1407 · Cited by 1
Yang, X., Fu, P., & Liu, H. L. (2026) · BMC Cancer · doi:10.1186/s12885-026-16411-6 · Cited by 3
“Additionally, neutrophils can block the activation of T-cells to cause immune evasion of tumor cells [51].”
Diehl, M. I., Basto, P. A., Abikenari, M. A., Linde, I. L., Okwan-Duodu, D. K., & Engleman, E. G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00968-2 · Cited by 1
“However, it can also support cancer growth through inhibition of senescence 100 or activation of the Hedgehog pathway 101 .”
Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression
Lai, P., Liu, L., Pernigoni, N., Du, Y., Braga, D., Troiani, M., Attanasio, G., Li, Y., Song, P., Pasquini, E., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01229-9 · Cited by 1
“Previous evidence from our team and others has shown that PMN-MDSCs can promote androgen-independent prostate tumor progression 19–21 .”
Self-citationTargeting immunosuppressive myeloid cells using nanocarriers to improve cancer immunotherapy
Sasso, M. S. (2015) · Padua@research (University of Padova) · Cited by 1
Cabazitaxel for the Treatment of Prostate Cancer
Kolinsky, M. P., Mehra, N., & Bono, J. S. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-31341-2_12 · Cited by 1
Comment limiter la progression des tumeurs prostatiques déficientes en PTEN ?
Grelet, É., Parisotto, M., & METZGER, D. (2018) · médecine/sciences · doi:10.1051/medsci/2018224 · Cited by 1
Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors
Jueliger, S., Taverna, P., Re, O. L., & Vinciguerra, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_166 · Cited by 1
Palminha, N. M., Hashish, S. A., Rabie, E., & Saber, S. (2022) · Nutritional neurosciences · doi:10.1007/978-981-16-9205-5_4 · Cited by 1
Caracterização do genoma e da resposta imune no microambiente tumoral de neoplasias PTEN-deficientes
Vidotto, T. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2019.tde-29072019-142549 · Cited by 1
Development of a novel allograft model of prostate cancer: a new tool to inform clinical translationPreprint
Haughey, C. M., Mukherjee, D., Steele, R. E., Popple, A. L., Dura-Perez, L., Pickard, A., Jain, S., Mullan, P. B., Williams, R. D., Oliveira, P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.16.942789 · Cited by 2
“High numbers of MDSCs in a Pten -/- setting provide a protective effect on PCa cells from senescence, therefore sustaining tumour growth 26 , 27 .”
BackgroundGarlanda, C., Ceglie, I. D., & Jaillon, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00178-2 · Cited by 1
TFXcan reveals transcription factor programs driving GWAS loci
Adeluwa, T., Salazar-Magaña, S., Sumner, S., Gona, S., Nyasimi, F., Carbonetto, P., Baca, S. C., Freedman, M., Gusev, A., Liu, B., et al. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101398
武内, 慎. (2015) · Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) · doi:10.14943/doctoral.k11956
Age-dependent sensitivity to antimitotics: the role of FOXM1 and its therapeutic potential
Vaz, S. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/gq0b-fc14
Identification of senescense-associated IL6 as a key component for cellular reprogramming
Pérez, N. A. (2020) · Hispana
Birth and death of cellular senescence
Wang, B. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.131223530
Remove tubular mill scale to improve completions
Bills, D. (1993) · World Oil; (United States)
An Overview of the Role of Senescence in Cancer
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v3i.77
“These cells block IL1α signalling and therefore antagonize the establishment of senescence in cancer cells and block immune surveillance [103,119,140].”
BackgroundData from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Chen, H.-A., Ho, Y.-J., Mezzadra, R., Adrover, J. M., Smolkin, R. M., Zhu, C., Woess, K., Bernstein, N., Schmitt, G., Fong, L. E., et al. (2023) · doi:10.1158/2159-8290.c.6549996
Reorganization of the Senescent Genome via Spatial CTCF Clustering
Palikyras, S. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9932
Mir, M. A., & Noor, I. (2023) · Springer eBooks · doi:10.1007/978-981-99-4657-0_15
The 29th Annual Prostate Cancer Foundation Scientific Retreat Report
Miyahira, A. K., & Soule, H. R. (2023) · The Prostate · doi:10.1002/pros.24640
“45 These data suggest that targeting MDSCs may have therapeutic potential in prostate cancer.”
BackgroundDynamique des interactions entre cellules immunes lors de régressions tumorales
Guérin, M. V. (2020) · theses.fr (ABES) · doi:10.70675/14fd93bfze334z4242z86f9z1bb7b8755bf0
Study of the role of the cyclin-dependent kinase inhibitor p21Waf1/Cip1 in cellular senescence
Zapata-Bodalo, I. (2022) · theses.fr (ABES) · doi:10.70675/db01e49aza2daz4404za0f1za3db90231ce9
Gong, L., Chen, J., Song, G., Wang, Y., Wang, Y., Ding, W., Peng, Y., Lou, Y., Murtola, T. J., Xu, K., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4804942
Self-citationInduction of astrocytes senescence by Plasmodium infection : role in cerebral malaria
Hellani, F. (2022) · theses.fr (ABES) · doi:10.70675/c2a869d4zae4fz44d6zbbd2z03500c51bea0
Oncogene inactivation-induced senescence facilitates tumor relapse
Schmitt, P., Hönig, K., Norcia, M. T., Nogueira, M. F., Flore, V., Vesperinas, I. S., Villoro-Agud, M., Peng, L., Safyürek, Z., Tariq, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75021-9
“Comparable remodeling has been reported in TIS models, where SASP factors recruit Gr-1 ⁺ myeloid cells or polarize macrophagestowardM2-likestates 51,62,63 .”
Janus-faced role of neutrophils in cancer
Mayadas, T. N., & Luo, H. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90001-8
A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy
Liu, Z., Mao, Y., Wang, S., Zheng, H., Yang, K., Yang, L., & Huang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1566227
Yu, B., Gao, F., Peng, J., Zhang, P., Zheng, G., & Zhou, S. (2025) · Medical Research Archives · doi:10.18103/mra.v13i4.6571
Chemokines and Chemokine Receptors in Cancer: An Update
Elemam, N. M., & Maghazachi, A. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00749-0_26
Tissue specificity and chromosomal alterations shape divergent immune programs in HRD tumorsPreprint
Gulhan, D., Barras, D., Mina, M., Ghisoni, E., Kim, Y., Viswanadham, V., Jin, H., Huber, F., Homicskó, K., Bassani‐Sternberg, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.13.681986 · Cited by 2
Fan, Y.-C., Fong, Y.-C., Kuo, C.-T., Li, C.-W., Chen, W.-Y., Lin, J.-D., Bürtin, F., Linnebacher, M., Bui, Q. T., Lee, K.-D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23930443
The Role of mtDNA in Senescence and Prostate Cancer Immune Response Regulation
Lai, P. (2024) · SERVAL (Université de Lausanne)
Guiho, R., Hamdi, H., Cooksley, G., Chang, T. H., Cao, L., Sigaud, R., Bliss, S., Vardon, A., Haston, S., Selt, F., et al. (2026) · Neuro-Oncology · doi:10.64898/2026.01.13.698644
Chen, S., Zhang, T., Qu, L., Han, S., Sun, M., & Yang, X. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202515201 · Cited by 1
Song, Y.-X., Xia, X.-L., Wu, Z.-M., Yao, Y., Liang, J.-Y., Guo, S. J., Yao, K., & Chang, H. (2026) · Discover Oncology · doi:10.1007/s12672-026-04559-3
“IL1RN, a marker of neutrophil activation [62, 63], was observed to be highly expressed in Neu_3, suggesting the activation state of the population.”
Rôle de LECT2 dans le microenvironnement immunitaire au cours de la cancérogènese hépatique
L’Hermitte, A. (2016) · theses.fr (ABES) · doi:10.70675/22c7ba64z940ez469ez8644z2fcf51db25f7
Caractérisation des bases moléculaires et cellulaires de l'Entose.
Voisin, L. (2016) · theses.fr (ABES) · doi:10.70675/af514e7ez614cz455bz9817z8b3e15549b83
Zhang, X., Yang, L., He, X., Zhao, M., Fang, Z., Xu, G., Duan, Z., & Luo, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.050 · Cited by 2
Bousset, L. (2019) · theses.fr (ABES) · doi:10.70675/45b0b676z18daz47a9zbb03zee607f300175 · Cited by 2
Characterization of Pten and Trp53 deficient prostatic tumors in mice
Bizri, R. E. (2018) · theses.fr (ABES) · doi:10.70675/887a45dbz93f0z4790z9840z71a317de4d2f
Madi-Berthélémy, P. O. (2018) · theses.fr (ABES) · doi:10.70675/451e797fz4661z4896z886bz419b6d675751
Khou, S. (2019) · theses.fr (ABES) · doi:10.70675/4a2404c5zaf36z4845z8431zbac35f2deb42
“TAN were shown to limit cancer cell senescence (Di Mitri et al., 2014).”
BackgroundDissecting the impact of cellular senescence on muscle regeneration
Cazin, C. (2020) · theses.fr (ABES) · doi:10.70675/42a7ff38zb338z4eb8za925z2ce0a01ee74e
The role of senescent tumor cells in carcinogenesis and antitumor immunity
Дмитриевна, Е. Д., Евгеньевна, М. Н., Slizhevskaya, E. V., Pinegin, B. V., & Pashenkov, M. V. (2026) · Immunologiya · doi:10.33029/0206-4952-2026-47-1-124-140
Pereira-Abrantes, M. (2023) · theses.fr (ABES) · doi:10.70675/9966b97fz01d9z430dzb93dzb43bababd470
Loverre, A. (2024) · theses.fr (ABES) · doi:10.70675/79e19555z0982z4d48zb235z1e77245236cf · Cited by 1
Metadata
- Authors
- Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., Da Silva-Alvarez, S., Collado, M., Eisenberger, M., Zhang, Z., Catapano, C., Grassi, F., & Alimonti, A.
- Affiliations
- Institute of Oncology Research (CH)
- Institute for Research in Biomedicine (CH)
- Complejo Hospitalario Universitario de Santiago (ES)
- Johns Hopkins University (US)
- University of Milan (IT)
- Corresponding author
- Alimonti, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-08-24
- Volume
- 515
- Issue
- 7525
- Pages
- 134-137
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1968545383
- Cited by
- 388
- References
- 32
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 31 · 2023: 39 · 2022: 35 · 2021: 32 · 2020: 44 · 2019: 22 · 2018: 33 · 2017: 30 · 2016: 26 · 2015: 23 · 2014: 3
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IRIS (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, senescence evasion, interleukin-1 receptor antagonist, senescence-associated secretory phenotype, chemoresistance, docetaxel, CXCR2 antagonist, innate immunity, tumor microenvironment
- MeSH terms
- Docetaxel, Animals, Cell Movement, Humans, Immunity, Innate, Male, Prostatic Neoplasms, Cellular Senescence, Disease Progression, Drug Resistance, Neoplasm, Tumor Escape, Receptors, Chemokine, Myeloid Cells, Receptors, Interleukin-8B, Taxoids, PTEN Phosphohydrolase, Mice, Interleukin-1alpha, Interleukin 1 Receptor Antagonist Protein, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.